Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
The company filed U.S. lawsuits against multiple businesses it says are selling unauthorized products tied to retatrutide, an investigational weight-loss candidate.
THE APEX TIMES
THE APEX TIMES
In a note cited by Yahoo Finance, Berenberg reduced its stance on Novo Nordisk while arguing that the “oral market” narrative has moved, with Eli Lilly positioned as the main beneficiary.
THE APEX TIMES
The biotech’s lead antibody, ABS-201, is drawing renewed attention after early Phase 1 results and a new Eli Lilly investment and development support tied to the asset.
THE APEX TIMES
Lilly is asking authorities to rein in unauthorized sellers as its experimental obesity medicine, retatrutide, faces expanding litigation and remains under regulatory review.
THE APEX TIMES
The company says it has identified and reported more than 200 sellers and individuals linked to unauthorized retatrutide offerings, drawing attention to the risks of counterfeit and unapproved weight-loss drugs as demand surges.
THE APEX TIMES
The company said it is advancing seltorexant for major depressive disorder into late-stage development and is expanding its outpatient approach in cardiology, indicating continued emphasis on specialty care across mental health and cardiovascular disease.
THE APEX TIMES
On its Q2 2026 conference call transcript published by Yahoo Finance, CVS Health said adjusted earnings per share jumped 42.5%, attributing the increase to margin recovery across operating segments.
THE APEX TIMES
A Yahoo Finance analysis points to new product activity, deal-making, and pipeline plans that are expected to matter more from 2029 onward, as Pfizer looks beyond the post-COVID era.
THE APEX TIMES
The company said it has filed six lawsuits targeting sellers it says are offering unofficial versions of its next-generation triple-therapy obesity drug, as it prepares an approval-related filing.
